Should You Continue to Hold Veracyte Stock in Your Portfolio?

Veracyte (VCYT) has consistently gained from the strength of its Afirma and Decipher tests. With Decipher expanding into metastatic and localized disease areas, the growth is likely to continue in the coming years. Simultaneously, the company continues to progress in its strategic long-term growth drivers. Meanwhile, declining biopharmaceutical revenues and macroeconomic impacts raise concerns for its operations. In the past year, this Zacks Rank #2 (Buy) stock has demonstrated impressive performance, outpe ...